Work

FURLONG study: reply on the patient reported outcome measures and thresholds

Year: 2025

Type: article

Abstract: We came across the publication entitled “Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer”.1 We would like to commend the authors for incorporating patient reported outcomes (PROs) in the evaluation of the treatment efficacy of furmonertinib. PROs and health-related quality of life assessments play an important role in the comprehensive evaluation of the impact of cancer treatments on the patient-reported experience, which will ultimately provide better informed shared-decision making between clinicians and their patients, and across different stakeholders.

Source: The Lancet Regional Health - Western Pacific

DOI: 10.1016/j.lanwpc.2025.101521

Authors: Ahu Alanya, Corneel Coens, Dagmara Kuliś, Jaap Reijneveld

Institutions: European Organisation for Research and Treatment of Cancer, European Organisation for Research and Treatment of Cancer, Amsterdam University Medical Centers, Stichting Epilepsie Instellingen Nederland

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,250